CNSYHealthcare · BiotechnologyThe 4 Wall Street analysts covering Cerenome, Inc. hold a median 12-month price target of $28 — +2834.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 13 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Cerenome, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (93): Smaller than most of the companies we track.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CNSY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +2834.7% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | Lake Street | Maintains | Buy | $50 → $31 |
| 11 Sept 2026 | Ascendiant Capital | Maintains | Buy | — |
| 11 Sept 2026 | Ascendiant Capital | Maintains | Buy | $57 → $43 |
| 8 June 2026 | Ascendiant Capital | Maintains | Buy | $65 → $57 |
| 8 June 2026 | Ascendiant Capital | Maintains | Buy | — |
| 9 Apr 2026 | Ascendiant Capital | Maintains | Buy | — |
| 31 Mar 2026 | D. Boral Capital | Downgrade | Hold | — |
| 19 Mar 2026 | D. Boral Capital | Maintains | Buy | — |
| 23 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 11 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 1 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Nov 2025 | Ascendiant Capital | Maintains | Buy | — |
| 20 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 6 Oct 2025 | Ascendiant Capital | Maintains | Buy | — |
| 25 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CNSY appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 13 Nov 2026, Cerenome, Inc. returned −92.7% against +13.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 72% of US stocks
Cheaper than 54% of US stocks
Cheaper than 61% of US stocks
Cheaper than 62% of US stocks
Higher than 3% of US stocks
Higher than 6% of US stocks
Higher than 30% of US stocks
Higher than 2% of US stocks
Higher than 2% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cerenome, Inc. has a market value of $7.2M and an enterprise value of −$1.3M.
Revenue in the twelve months to 30 June 2026: $0.0. The latest quarter shrank 70.4% year on year.
Net income over the same four quarters: −$26.1M.
Free cash flow in the twelve months to 30 June 2026: −$23.5M.
Trailing P/E: 0.5×; forward P/E: −0.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Cerenome, Inc. employs 28 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Cerenome, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Cerenome reported a third-quarter loss of $1.14 per share, compared with the Zacks consensus estimate of a $0.98 loss. The company recorded a loss of $1 per share in the year-earlier quarter.
Why it matters — CNSY watchers may note the quarterly loss was larger than the consensus estimate and the year-ago loss.
Cerenome announced its financial results for the third quarter ended September 30, 2026, and provided an overview of recent business progress. The headline highlights REYOBIQ ReSPECT-LM data and CNSide commercial and reimbursement progress.
Why it matters — The update concerns quarterly results and progress in areas of Cerenome’s diagnostics and radiopharmaceutical business that CNSY watchers may follow.
Cerenome announced a conference call for November 16, 2026, at 8:30 a.m. Eastern Time. The company plans to review REYOBIQ ReSPECT-LM clinical data scheduled for presentation at SNO on November 13 and provide a CNSide commercial update.
Why it matters — The call will provide CNSY watchers with information on the planned clinical-data review and a commercial update for CNSide.
Cerenome appointed director Ron “Ronnie” Andrews to the newly created role of Chief Business Officer. He will continue serving on the company's Board of Directors.
Why it matters — The appointment adds a business officer role while retaining Andrews on the board, a leadership change for CNSY watchers to note.
Cerenome announced a national in-network agreement with Aetna for CNSide®. The company said it is now contracted with approximately 85% of private payers in the US, representing approximately 190 million covered lives.
Why it matters — The Aetna agreement and reported payer coverage provide CNSY watchers information about the reach of CNSide® among private payers.
The 4 Wall Street analysts covering Cerenome, Inc. have a median 12-month price target of $28, with estimates ranging from $12 to $43. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Cerenome, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cerenome, Inc. 14 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Nov 2026, Cerenome, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (93 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +2834.7% from the last close, and Ticker Nerd's factor model ranks Cerenome, Inc. 14 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Cerenome, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNSY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $43 over the next 12 months.
Cerenome, Inc. returned -92.7% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Cerenome, Inc. is a clinical-stage biotechnology company focused on central nervous system oncology.
The most recent item we track (Zacks Investment Research, 14 Nov 2026): "Cerenome (CNSY) Reports Q3 Loss, Beats Revenue Estimates". Cerenome reported a third-quarter loss of $1.14 per share, compared with the Zacks consensus estimate of a $0.98 loss. The company recorded a loss of $1 per share in the year-earlier quarter.
Cerenome, Inc. is a clinical-stage biotechnology company focused on central nervous system oncology. Cerenome develops precision diagnostics, targeted radiotherapeutics, and data-driven clinical tools designed to support the detection, characterization, and treatment of CNS cancers. Its current portfolio centers on cerebrospinal fluid-based diagnostic testing for monitoring disease in the brain and spinal cord, alongside investigational radiopharmaceutical therapies for conditions such as recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also works with patient data analytics and artificial intelligence to integrate diagnostic and therapeutic insights into a more connected oncology platform. Headquartered in Houston, Texas, Cerenome serves the specialized market for rare and difficult-to-treat CNS malignancies, where its products and programs are positioned within hospital, research, and clinical care settings.
CEO Dr. Marc H. Hedrick M.B.A., M.D. · 28 employees · United States · https://cerenome.com
